Acute hemorrhagic myocardial necrosis and sudden death of rats exposed to a combination of ephedrine and caffeine

Toxicological Sciences

Volumn 83, Issue 2, 2005, Pages 388-396

  Nyska, Abraham ^a   Murphy, Elizabeth ^a   Foley, Julie F ^a   Collins, Bradley J ^a   Petranka, John ^a   Howden, Reuben ^a   Hanlon, Paul ^a   Dunnick, June K ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Apoptosis; Caffeine; Cardiotoxicity; Coagulative necrosis; Ephedrine; Ischemia

Indexed keywords

CAFFEINE; CASPASE 3; EPHEDRINE; HISTONE H2A;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLEEDING; BODY SURFACE; CELL NUCLEUS; CONTROLLED STUDY; CORONARY ARTERY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART MUSCLE NECROSIS; HEART MUSCLE PERFUSION; HEART RIGHT VENTRICLE; HEART VENTRICLE SEPTUM; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; MUSCLE ATROPHY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; RISK ASSESSMENT; STROKE; STRUCTURE ANALYSIS; SUDDEN DEATH; VASOCONSTRICTION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADRENERGIC AGENTS; ANIMALS; CAFFEINE; CASPASE 3; CASPASES; CENTRAL NERVOUS SYSTEM STIMULANTS; DEATH, SUDDEN; DRUG COMBINATIONS; DRUG INTERACTIONS; EPHEDRINE; HEART; HEMORRHAGE; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; RATS; RATS, INBRED F344; STAINING AND LABELING;

ANIMALIA; EPHEDRA; PAULLINIA CUPANA;

EID: 13644267293     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfi034     Document Type: Article

References (45)

1. Astrup, A., Toubro, S., Cannon, S., Hein, P., and Madsen, J. (1991). Thermogenic synergism between ephedrine and caffeine in healthy volunteers, a double-blind, placebo-controlled study. Metabolism 40, 323-329.
2. Borutaite, V., Budriunaite, A., Morkuniene, R., and Brown, G. C. (2001). Release of mitochondrial cytochrome c and activation of cytosolic caspases induced by myocardial ischaemia. Biochim. Biophys. Acta 1537, 101-109.
3. Cockings, J. G., and Brown, M. (1997). Ephedrine abuse causing acute myocardial infarction. Med. J. Aust. 167, 199-200.
4. Cohn, J. N. (1965). Comparative cardiovascular effects of tyramine, ephedrine, and norepinephrine in man. Circ. Res. 26, 174-182.
5. Enders, J. M., Dobesh, P. P., and Ellison, J. N. (2003). Acute myocardial infarction induced by ephedrine alkaloids. Pharmacotherapy 23, 1645-1651.
6. Foxford, R. J., Sahlas, D. J., and Wingfield, K. A. (2003). Vasospasm-induced stroke in a varsity athlete secondary to ephedrine ingestion. Clin. J. Sport Med. 13, 183-185.
7. Franciosa, J. A., and Cohn, J. N. (1979). Hemodynamic effects of oral ephedrine given alone or combined with nitroprusside infusion in patients with severe left ventricular failure. Am. J. Cardiol. 43, 79-85.
8. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. 50, 219-244.
9. Goyns, M. H., Charlton, M. A., Dunford, J. E., Lavery, W. L., Merry, B. J., Salehi, M., and Simõnes, D. C. (1998). Differential display analysis of gene expression indicates that age-related changes are restricted to a small cohort of genes. Mech. Ageing Dev. 101, 73-90.
10. Greaves, P. (2000). Cardiovascular system. In Histopathology of Preclinical Toxicity Studies (P. Greaves, Ed.), 2nd ed., pp. 254-311. Elsevier, New York.
11. Gurley, B. J., Wang, P., and Gardner, S. F. (1998). Ephedrine type alkaloid content of nutritional supplements containing Ephedra sinica (Ma-huang) as determined by high performance liquid chromatography. J. Pharm. Sci. 87, 1547-1553.
12. Haller, C. A., and Benowitz, N. L. (2000). Adverse cardiovascular and central nervous system events associated with dietary supplements containing Ephedra alkaloids. N. Engl. J. Med. 343, 1833-1838.
13. Haller, C. A., Duan, M., Benowitz, N. L., and Jocob, P. I. (2004). Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements. J. Anal. Toxicol. 28, 145-151.
14. Haller, C. A., Jacob, P. I., and Benowitz, N. L. (2002). Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin. Pharmacol. Ther. 71, 421-432.
15. Hirabayashi, Y., Saitoh, K., Fukuda, H., Mitsuhata, H., and Shimizu, R. (1996). Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. Anesthesiology 84, 221-224.
16. Isoyama, S., and Nitta-Komatsubara, Y. (2002). Acute and chronic adaptation to hemodynamic overload and ischemia in the aged heart. Heart Fail. Rev. 7, 63-69.
17. Jacob, P. I., Haller, C. A., Duan, M., Yu, L., Peng, M., and Benowitz, N. L. (2004). Determination of ephedra alkaloid and caffeine concentrations in dietary supplements and biological fluids. J. Anal. Toxicol. 28, 152-159.
18. Johannsson, S. (1981). Cardiovascular lesions in Sprague-Dawley rats induced by long-term treatment with caffeine. Acta Pathol. Microbiol. Scand. A 89, 185-191.
19. Krome, C. N., and Tucker, A. M. (2003). Cardiac arrhythmia in a professional football player: Was ephedrine to blame? Physician and Sportsmedicine 31, 21-25.
20. Kumar, D., and Jugdutt, B. I. (2003). Apoptosis and oxidants in the heart. J. Lab. Clin. Med. 142, 288-297.
21. Lee, M. K., Cheng, B. W., Che, C. T., and Hsieh, D. P. (2000). Cytotoxicity assessment of Ma-huang (ephedra) under different conditions of preparation. Toxicol. Sci. 56, 424-430.
22. Li, Y., Sun, X., Wang, L., Zhou, Z., and Kang, Y. J. (2002). Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc. Toxicol. 2, 63-73.
23. Lustik, S. J., Chhibber, A. K., van Vliet, M., and Pomerantz, R. M. (1997). Ephedrine-induced coronary artery vasospasm, in a patient with prior cocaine use. Anesth. Analg. 84, 931-933.
24. McBride, B. F., Karapanos, A. K., Krudysz, A., Kluger, J., Coleman, C. I., and White, C. M. (2004). Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine. JAMA 291, 216-221.
25. Milei, J., and Bolomo, N. J. (1983). A routine method for diagnosis of early myocardial infarction. Int.l J. Cardiol. 4, 319-321.
26. Milei, J., and Storino, R. (1986). Early myocardial infarction. A feasible histologic diagnostic procedure. Jpn. Heart J. 27, 307-319.
27. Miller, S. C., and Waite, C. (2003). Ephedrine-type alkaloid-containing dietary supplements and substance dependence. Psychosomatics 44, 508-511.
28. Minematsu, S., Kobayashi, Y., Kobayashi, N., Fufii, Y., Aburada, M., and Yamashita, M. (1991). Acute ephedrae herba and ephedrine poisoning in mice. Japanese Journal of Toxicology 4, 143-149.
29. Naka, Y., Sawa, Y., Nishimura, M., Hirata, N., Ueda, H., Ohtake, S., and Matsuda, H. (2003). Participation of caspase-3-like protease in necrotic cell death of myocardium during ischemia-reperfusion injury in rat hearts. Circ. J. 67, 248-252.
30. National Toxicology Program (1986). Toxicology and carcinogenesis studies of ephedrine sulfate in F344/N rats and B6C3F1 mice (feed studies). NTP Technical Report Series 307. NIH Publication 86-2563.
31. Nurminen, M. L., Niittynen, L., Korpela, R., and Vapaatalo, H. (1999). Coffee, caffeine, and blood pressure: A critical review. Eur. J. Clin. Nutr. 53, 831-839.
32. O'Neil, M. J., Smith, A., Heckelman, P. E., Obenchain, J. R., Jr., Gallipeau, J. A. R., D'Arecca, M. A., and Budavari, S., Eds. (2001). The Merck Index. Merck Research Laboratories, Whitehouse Station, NJ.
33. Persky, A. M., Berry, N. S., Pollack, G. M., and Brouwer, K. L. R. (2004). Modelling the cardiovascular effects of ephedrine. Br J. Clin. Pharmacol. 57, 552-562.
34. Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y., and Bonner, W. M. (2000). Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2Ax histone at serine 139. J. Biol. Chem. 275, 9390-9395.
35. Rose'Meyer, R. B., Headrick, J. P., Pearl, J. N., Harrison, G. J., Garnham, B. G., and Willis, R. J. (2001). Acute but not chronic caffeine impairs functional responses to ischaemia-reperfusion in rat isolated perfused heart. Clin. Exp. Pharmacol. Physiol. 28, 19-24.
36. Samenuk, D., Link, M. S., Hormoud, M. K., Caonteras, R., Theoharides, T. C., Wang, P. J., and Estes, N. A. I. (2002). Adverse cardiovascular events temporally associated with Ma Huang, a herbal source of ephedrine. Mayo Clin. Proc. 77, 12-16.
37. Talasz, H., Helliger, W., Sarg, B., Debbage, P. L., Puschendorf, B., and Lindner, H. (2002). Hyperphosphorylation of histone H2A.X and dephosphorylation of histone H1 subtypes in the course of apoptosis. Cell Death Differ. 9, 27-39.
38. Tong, C., and Eisenach, J. C. (1992). The vascular mechanism of ephedrine's beneficial effect on uterine perfusion during pregnancy. Anesthesiology 76, 792-798.
39. United States Food and Drug Administration (2004). Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk; Final rule. Federal Register, February 11, 2004, 6788-6854.
40. Vinten-Johansen, J. (2004). Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cadiovasc. Res. 61, 481-497.
41. Vlachopoulos, C., Hirata, K., and O'Rourke, M. F. (2002). Effect of caffeine on aortic elastic properties and wave reflection. J. Hypertens. 21, 563-570.
42. Weiner, N. (1980). Norepinephrine, epinephrine, and the sympathomimetic amines. In The Pharmacologic Basis of Therapeutics (A. G. Gilman, L. Goodman, and A. Gilman, Eds.), 6th ed., pp. 138-175. MacMillan, New York.
43. White, L. M., Gardner, S. F., Gurley, B. J., Marx, M. A., Wang, P. L., and Estes, E. (1997). Pharmacokinetics and cardiovascular effects of Ma-Huang (Ephedra sinica) in normotensive adults. J. Clin. Pharmacol. 37, 116-122.
44. Wilkinson, G. R., and Beckett, A. H. (1968). Absorption, metabolism, and excretion of the ephedrines in man. II. J. Pharm. Sci. 57, 1933-1938.
45. Yuan, J. (1993). Modeling blood/plasma concentration in dosed feed and dosed drinking water toxicology studies. Toxicol. Appl. Pharmacol. 119, 131-141.